Molecular pathological epidemiology of colorectal cancer in Chinese patients with KRAS and BRAF mutations

Oncotarget

Volumn 6, Issue 37, 2015, Pages 39607-39613

  Li, Wenbin ^a   Qiu, Tian ^a   Ling, Yun ^a   Guo, Lei ^a   Li, Lin ^a   Ying, Jianming ^a  

^a CANCER HOSPITAL   (China)

Author keywords

BRAF; Colorectal cancer; KRAS; Molecular pathological epidemiology; Mutation

Indexed keywords

B RAF KINASE; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; K RAS PROTEIN; TUMOR MARKER; BRAF PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; PROTEIN P21;

ARTICLE; CANCER PATIENT; CANCER RISK; CHINESE; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR EPIDEMIOLOGY; MOLECULAR MECHANICS; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; PROTEIN BLOOD LEVEL; SEX RATIO; SMOKING; WILD TYPE; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CHINA; COLORECTAL TUMOR; EPIDEMIOLOGY; ETHNOLOGY; GENETICS; MULTIVARIATE ANALYSIS; MUTATION; PATHOLOGY; PROCEDURES; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

ASIAN CONTINENTAL ANCESTRY GROUP; BIOMARKERS, TUMOR; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHINA; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); RISK ASSESSMENT; RISK FACTORS;

EID: 84950150848     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5551     Document Type: Article

References (34)

1. Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. J Mol Diagn. 2008; 10:13-27.
2. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol. 2011; 6:479-507.
3. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487:330-337.
4. Zlobec I, Kovac M, Erzberger P, Molinari F, Bihl MP, Rufle A, Foerster A, Frattini M, Terracciano L, Heinimann K, Lugli A. Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer. Int J Cancer. 2010; 127:2569-2575.
5. Ward RL, Todd AV, Santiago F, O'Connor T, Hawkins NJ. Activation of the K-ras oncogene in colorectal neoplasms is associated with decreased apoptosis. Cancer. 1997; 79:1106-1113.
6. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007; 357:2040-2048.
7. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008; 359:1757-1765.
8. Bazan V, Migliavacca M, Zanna I, Tubiolo C, Grassi N, Latteri MA, La Farina M, Albanese I, Dardanoni G, Salerno S, Tomasino RM, Labianca R, Gebbia N, Russo A. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol. 2002; 13:1438-1446.
9. Chen CC, Er TK, Liu YY, Hwang JK, Barrio MJ, Rodrigo M, Garcia-Toro E, Herreros-Villanueva M. Computational analysis of KRAS mutations: implications for different effects on the KRAS p.G12D and p.G13D mutations. PLoS One. 2013; 8:e55793.
10. Mao C, Huang YF, Yang ZY, Zheng DY, Chen JZ, Tang JL. KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and metaanalysis. Cancer. 2013; 119:714-721.
11. Yoon HH, Tougeron D, Shi Q, Alberts SR, Mahoney MR, Nelson GD, Nair SG, Thibodeau SN, Goldberg RM, Sargent DJ, Sinicrope FA. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res. 2014; 20:3033-3043.
12. Imamura Y, Morikawa T, Liao X, Lochhead P, Kuchiba A, Yamauchi M, Qian ZR, Nishihara R, Meyerhardt JA, Haigis KM, Fuchs CS, Ogino S. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res. 2012; 18:4753-4763.
13. Li W, Qiu T, Zhi W, Shi S, Zou S, Ling Y, Shan L, Ying J, Lu N. Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages. BMC Cancer. 2015; 15:340.
14. Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. N Engl J Med. 2009; 361:98-99.
15. Yaeger R, Cercek A, Chou JF, Sylvester BE, Kemeny NE, Hechtman JF, Ladanyi M, Rosen N, Weiser MR, Capanu M, Solit DB, D'Angelica MI, Vakiani E, Saltz LB. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer. 2014; 120:2316-2324.
16. Ogino S, Stampfer M. Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. J Natl Cancer Inst. 2010; 102:365-367.
17. Ogino S, Chan AT, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut. 2011; 60:397-411.
18. BM, Meyerhardt JA, Meissner A, Schernhammer ES, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol. 2013; 26:465-484.
19. Bishehsari F, Mahdavinia M, Vacca M, Malekzadeh R, Mariani-Costantini R. Epidemiological transition of colorectal cancer in developing countries: environmental factors, molecular pathways, and opportunities for prevention. World J Gastroenterol. 2014; 20:6055-6072.
20. Liang PS, Chen TY, Giovannucci E. Cigarette smoking and colorectal cancer incidence and mortality: systematic review and meta-analysis. Int J Cancer. 2009; 124:2406-2415.
21. Porta M, Crous-Bou M, Wark PA, Vineis P, Real FX, Malats N, Kampman E. Cigarette smoking and K-ras mutations in pancreas, lung and colorectal adenocarcinomas: etiopathogenic similarities, differences and paradoxes. Mutat Res. 2009; 682:83-93.
22. Samadder NJ, Vierkant RA, Tillmans LS, Wang AH, Lynch CF, Anderson KE, French AJ, Haile RW, Harnack LJ, Potter JD, Slager SL, Smyrk TC, Thibodeau SN, Cerhan JR, Limburg PJ. Cigarette smoking and colorectal cancer risk by KRAS mutation status among older women. Am J Gastroenterol. 2012; 107:782-789.
23. Wark PA, Van der Kuil W, Ploemacher J, Van Muijen GN, Mulder CJ, Weijenberg MP, Kok FJ, Kampman E. Diet, lifestyle and risk of K-ras mutation-positive and-negative colorectal adenomas. Int J Cancer. 2006; 119:398-405.
24. Weijenberg MP, Aardening PW, de Kok TM, de Goeij AF, van den Brandt PA. Cigarette smoking and KRAS oncogene mutations in sporadic colorectal cancer: results from the Netherlands Cohort Study. Mutat Res. 2008; 652:54-64.
25. Curtin K, Samowitz WS, Wolff RK, Herrick J, Caan BJ, Slattery ML. Somatic alterations, metabolizing genes and smoking in rectal cancer. Int J Cancer. 2009; 125:158-164.
26. Martinez ME, Maltzman T, Marshall JR, Einspahr J, Reid ME, Sampliner R, Ahnen DJ, Hamilton SR, Alberts DS. Risk factors for Ki-ras protooncogene mutation in sporadic colorectal adenomas. Cancer Res. 1999; 59:5181-5185.
27. Samowitz WS, Albertsen H, Sweeney C, Herrick J, Caan BJ, Anderson KE, Wolff RK, Slattery ML. Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. J Natl Cancer Inst. 2006; 98:1731-1738.
28. Limsui D, Vierkant RA, Tillmans LS, Wang AH, Weisenberger DJ, Laird PW, Lynch CF, Anderson KE, French AJ, Haile RW, Harnack LJ, Potter JD, Slager SL, Smyrk TC, Thibodeau SN, Cerhan JR, et al. Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst. 2010; 102:1012-1022.
29. Wan ES, Qiu W, Baccarelli A, Carey VJ, Bacherman H, Rennard SI, Agusti A, Anderson W, Lomas DA, Demeo DL. Cigarette smoking behaviors and time since quitting are associated with differential DNA methylation across the human genome. Hum Mol Genet. 2012; 21:3073-3082.
30. Lee KW, Pausova Z. Cigarette smoking and DNA methylation. Front Genet. 2013; 4:132.
31. Hinoue T, Weisenberger DJ, Lange CP, Shen H, Byun HM, Van Den Berg D, Malik S, Pan F, Noushmehr H, van Dijk CM, Tollenaar RA, Laird PW. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res. 2012; 22:271-282.
32. Vukobrat-Bijedic Z, Husic-Selimovic A, Sofic A, Bijedic N, Bjelogrlic I, Gogov B, Mehmedovic A. Cancer Antigens (CEA and CA 19-9) as Markers of Advanced Stage of Colorectal Carcinoma. Med Arch. 2013; 67:397-401.
33. Takakura Y, Ikeda S, Imaoka Y, Urushihara T, Itamoto T. An elevated preoperative serum carbohydrate antigen 19-9 level is a significant predictor for peritoneal dissemination and poor survival in colorectal cancer. Colorectal Dis. 2015; 17:417-425.
34. Smith CG, Fisher D, Claes B, Maughan TS, Idziaszczyk S, Peuteman G, Harris R, James MD, Meade A, Jasani B, Adams RA, Kenny S, Kaplan R, Lambrechts D, Cheadle JP. Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy +/-cetuximab. Clin Cancer Res. 2013; 19:4104-4113.